German ADC specialist Tubulis closed an oversubscribed Series C round—one of the largest European private raises this year—to accelerate clinical development of its lead antibody‑drug conjugate TUB‑040 and expand into earlier‑line indications. The financing, reported in the high‑hundreds of millions of dollars, will support broader patient cohorts and additional tumor types as the company prepares to present first clinical data at a major oncology meeting. Tubulis said the cash will also underwrite pipeline and manufacturing work to validate in‑house ADC design and higher drug‑to‑antibody ratio strategies. Investors highlighted the round as evidence of deep appetite for differentiated ADC platforms despite crowded oncology markets.